CN107375532A - Black fruit fructus lycii extract is preparing the purposes in treating gout product - Google Patents
Black fruit fructus lycii extract is preparing the purposes in treating gout product Download PDFInfo
- Publication number
- CN107375532A CN107375532A CN201710687785.8A CN201710687785A CN107375532A CN 107375532 A CN107375532 A CN 107375532A CN 201710687785 A CN201710687785 A CN 201710687785A CN 107375532 A CN107375532 A CN 107375532A
- Authority
- CN
- China
- Prior art keywords
- medicine
- fructus lycii
- food
- black fruit
- health products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 38
- 201000005569 Gout Diseases 0.000 title claims abstract description 31
- 239000000284 extract Substances 0.000 title description 7
- 239000003814 drug Substances 0.000 claims abstract description 32
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 230000036541 health Effects 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 229940100601 interleukin-6 Drugs 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 12
- 230000001154 acute effect Effects 0.000 claims description 7
- 229930014669 anthocyanidin Natural products 0.000 claims description 7
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 7
- 235000008758 anthocyanidins Nutrition 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 3
- 102000010906 Cyclooxygenase 1 Human genes 0.000 claims description 3
- 108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 108010088383 interleukin-6 receptor alpha Proteins 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 17
- 238000005259 measurement Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000001431 Hyperuricemia Diseases 0.000 description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000208292 Solanaceae Species 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000169546 Lycium ruthenicum Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003284 horn Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides the purposes the invention provides black fruit fructus lycii ethanol extract in the food, medicine or health products of prevention or/and treatment gout is prepared.Present invention research is found, can effectively be prevented or be treated the gout caused by MSU using black fruit fructus lycii ethanol extract, have good functions of detumescence, relieving inflammation effect, and new product is provided for clinical prevention or/and treatment gout.
Description
Technical field
The present invention relates to the new application of black fruit fructus lycii extract.
Background technology
Gout (gout) is that long-term disorders of purine metabolism, blood uric acid increase one group of different substantiality disease for causing tissue damage.
Clinical characters be hyperuricemia (hyperuricemia, HUA), gouty acute arthritis recurrent exerbation, tophaceous deposition,
Characteristic chornic arthritis and joint deformity, often involve kidney and cause arteriosclerotic kidney and kidney calculus urate to be formed.Gout
Biochemical marker be hyperuricemia, the lithate for referring to extracellular fluid is in over-saturation state.Lithate (monosodium urate
Crystal, MSU) deposited in crystalline form in joint and periarticular tissue so as to cause a series of acute inflammatory reactions, be
Gout.It is generally acknowledged that Xue Niao Suan≤416 μm ol/L are hyperuricemia, and about 5%-12% Patients with Hyperuricemia can develop
As gout, the chance that serum uric acid level continues to have 70%-90% in 540 μm of ol/L persons obtains gout.
According to《Chinese medicinal application detection》Statistics, Patients with Hyperuricemia number in China's is up to 1.2 hundred million at present, and by high lithemia
The disease rates that mass formed by blood stasis develops into gout are about 1/10.China's gout number of the infected is in 2015 up to 75,000,000, and gout is sent out
Sick rate also significantly rises with 7.5% speed every year, and 1/5 gout patients have lost viability, the gout patients course of disease
More than 10 years, easily trigger the uremia for being difficult to cure, heavy psychological pressure and financial burden are brought to patient and family.It is high
Uricacidemia and the disease such as primary gout and obesity, hyperlipidemia, high blood pressure, diabetes, coronary heart disease are in notable positive
Close.Therefore, gout is a kind of serious metabolic disease for endangering human health especially as diabetes.
For the treatment of acute stage gout, clinical medicine mainly from non-steroid anti-inflammatory drug (NASIDs), colchicin,
Cortex hormone of aadrenaline and antalgesic these four medicines.However, although these medicine anti-inflammatory analgetics act on fast, medical expense
Height, and most drug toxic side effect is quite obvious.
Black fruit fructus lycii (Lyciumruthenicum Murray) is the perennial shrub of Solanaceae (Solanaceae) Lycium
Low-temperature dark dries berry, black fruit fructus lycii is sweet, the mild-natured, heat that clears away heart-fire, for treating cardiopyretic disease, heart disease, irregular menstruation, menopause
Etc. illness.Black fruit fructus lycii is widely used as common edible berry or health food at present, and still, yet there are no will be black
Fruit matrimony vine or its extract are used for the research report for treating gout.
The content of the invention
Based on above-mentioned present situation, the present invention intends providing medical usage of the black fruit fructus lycii ethanol extract in terms of gout.
Specifically, the invention provides black fruit fructus lycii ethanol extract to prepare food, the medicine of prevention or/and treatment gout
Purposes in product or health products.
In the present invention, the black fruit fructus lycii ethanol extract is that concentration is in more than 95%v/v with black fruit fructus lycii raw material
Ethanol extract to obtain.
Further, the black fruit fructus lycii ethanol extract is that concentration is in more than 95%v/v with black fruit fructus lycii raw material
Ethanol extract to obtain；Further, in the ethanol extract preparation process, answer lucifuge to operate, also needed after extraction through filtering
Processing.Lucifuge operates, and is advantageous to protect the extraction to anthocyan composition；Suction filtration can remove insoluble matter, a certain amount of protein,
The compositions such as polysaccharide.
In the present invention, the content of anthocyanidin is more than 50% in black fruit fructus lycii ethanol extract；Further, anthocyanidin contains
Amount is in 80%-95%.According to general knowledge known in this field, plant extracts active component refers to the content of the constituents 50%
More than.In black fruit fructus lycii ethanol extract of the present invention, anthocyan component content is maintained at more than 50%, the extract
Black fruit fructus lycii anthocyanidin position can be considered as or it is total cyanidin extract.In an embodiment of the invention, this hair
Anthocyanidin content is about 80~90%, such as 80%, 85%, 90% etc. in the ethanol extract of bright preparation.
Further, the food, medicine or health products are prevention or/and the food, medicine or the guarantor that treat acute gout
Strong product.
Gout of the present invention, including at least acute attack arthritis, tophus formation, tophaceous chornic arthritis
Deng.
Further, the food, medicine or health products are the food, medicine or health products of anti-inflammatory.
Further, the food, medicine or health products are reduction or food, medicine or the health care of removing urate crystal
Product.
Wherein, the food, medicine or health products are to reduce hs-CRP in blood, tumor necrosis factor α, white
Food, medicine or the health products of the content of at least one of interleukin -6, cyclooxygenase 1, prostaglandin E.
Wherein, it was unexpectedly observed that in the influence to inflammatory factor in experiment, the effect of black fruit fructus lycii ethanol extract is imitated
Fruit is nearly all not so good as positive control medicine Indomethacin；But the reduction effect to interleukin-6, black fruit fructus lycii ethanol extract
Effect under high dose, is significantly better than Indomethacin, and this explanation black fruit fructus lycii ethanol extract is made in the suppression to interleukin-6
With positive control medicine to be substantially better than.
Interleukin-6, abbreviation interleukin 6 (IL-6), is a kind of cell factor, belongs to one kind of interleukins.It
It is by fibroblast, Monocytes/Macrophages, T lymphocytes, bone-marrow-derived lymphocyte, epithelial cell, horn cell and a variety of knurls
Produced by cell.IL-1, TNF-a, PDGF, virus infection, double-stranded RNA and c AMP etc., it can induce normal cell and produce white be situated between
Element 6.Interleukin 6, which can stimulate, to be participated in the cell propagation of immune response, breaks up and improve its function.It has now been discovered that white be situated between
The abnormal rise of element 6, often has close association, as thrombocythemia, diseases associated with inflammation, immune response are different with multiple physical body disease
Often, osteoporosis, chronic joint rheumatism, hypercalcemia, Huppert's disease, cachexia, ephritis etc., it can participate in inflammatory reaction
And exothermic reaction.Therefore, based on the present invention to black fruit fructus lycii ethanol extract to the significant inhibitory action of interleukin-6, the present invention
Additionally provide purposes of the black fruit fructus lycii ethanol extract in interleukin-6 inhibitor is prepared.
Further, the present invention can utilize the treatment of black fruit fructus lycii ethanol extract and interleukin-6 increases extremely or exception
Activate related disease.
Present invention also offers purposes of the black fruit fructus lycii ethanol extract in tumor necrosis factor alpha inhibitors are prepared.
Present invention research is found, can effectively be prevented or be treated the gout caused by MSU using black fruit fructus lycii ethanol extract,
With good functions of detumescence, relieving inflammation effect, new product is provided for clinical prevention or/and treatment gout.
Based on above-mentioned discovery, present invention also offers the product containing black fruit fructus lycii ethanol extract prepare prevention or/
With the purposes in the food, medicine or health products for the treatment of gout.
Active component in above-mentioned " product " comprises at least black fruit fructus lycii ethanol extract one kind, it is of course also possible to only
Only using black fruit fructus lycii ethanol extract as active component.In addition, can also include in the product related auxiliary material or it is complementary into
Point.
The product is given by intestines and stomach absorption features, can prepare different preparation types according to the actual requirements,
Such as liquid form, solid form.Based on different preparation types, different auxiliary materials can be selected.
Brief description of the drawings
Fig. 1 rat paw edema measurement results, wherein, A1=low dose groups, A2=middle dose groups, A3=high dose groups, with
Blank group is that reference group is variance analysis, P**<0.01 is extremely notable, p*<0.05 is notable.
Embodiment
With reference to specific embodiment, the present invention is further elaborated, but the present invention does not limit to and following examples,
The raw material can obtain from open commercial sources unless otherwise specified.
1. sample preparation
Ethanol extract:45 DEG C of lucifuges of black fruit fructus lycii are dried (97%) 40 DEG C of lucifuge of 72h → 20 eye mesh screens → edible alcohol and surpassed
Sound extracts 8 times → 50 DEG C lucifuge spin concentrations, make ethanol dissolved after fully volatilizing with distilled water → lucifuge is freeze-dried 48h.
After measured, the content of anthocyanidin is 87% in above-mentioned ethanol extract.
2. experimental animal
Rat:SD kinds, SPF level 180-200g, male, sell unit:Hunan SJA Laboratory Animal Co. , Ltd,
Quality testing unit:Hunan SJA Laboratory Animal Co. , Ltd, sell unit credit number:SCXK (Hunan) 2013-
0004, experimental unit's licensing numbering:SYXK (green grass or young crops) 2012-0001
3. rat acute Gout Model pharmacological research experimental method
Animal packet:Adaptability is raised one week after packet, is divided into 6 groups, each group 10, is respectively:Blank group, model group,
Positive drug group, the low middle high dose group of test specimen is 3 groups, amounts to 6 groups
Sample:Black fruit fructus lycii ethanol extract is formulated as 8g/100ml, low middle high dose group difference with sterilized water for injection
For 100mg/kg, 200mg/kg, 400mg/kg, i.e., 0.25ml, 0.5ml, 1ml are filled respectively.It is positive per average daily administration before measure
Medicine is identical.
Acute gout derivant MSU:40mg/ml, and ultrasonic 10min are formulated as with 0.9%NaCl, in Rat Right foot foot pad
Intracutaneous injection 0.1ml
Positive drug:Indomethacin is formulated as 50mg/100ml with 0.9%NaCl, is administered by 3mg/kg, fills 1.2ml,
Use preceding ultrasonic 10min
Foot swelling determines:Every group of Rat Right metapedes thickness is determined with electronic vernier caliper by a people respectively, is determined respectively
Right metapedes thickness after 0h, 4h, 24h, 48h, 72h
Exoculation pearl takes blood and executions that dislocates after observation 72h, before execution 12h fasting can't help water, liver, spleen, kidney, the right side are taken after dissection
Metapedes
Blood:Take blood room temperature place 2h after 2000r centrifugation 5min after take supernatant 3000r centrifugation 5min take serum to be put into -80
DEG C standby of refrigerator
Liver, spleen, kidney, right metapedes:Dissection, takes liver, spleen, kidney, right metapedes, after physiological saline Rapid Cleaning two times, uses yarn
Cloth absorbs water, and is put into valve bag after weighing, is put into the standby of -80 DEG C of refrigerators
4 result of the tests
4.1 foot swelling measurement results
Data are with 10 rat paw edemas in Fig. 1Variance analysis is carried out with one-way anova.
As seen from the figure：0h each groups Rat Right metapedes measurement result illustrates the right metapedes thickness base of each group mouse without significant difference
This is consistent, and the right metapedes thickness of measurement result display model group significantly increases after 4h and change is little in 72, illustrates that we make
Mould success；Foot swelling, which just occurs, in the right metapedes of positive drug after 4h significantly reduces, and middle dose group foot occurs in 24h with high dose group and swollen
It is swollen to significantly reduce, primarily determine that middle dose group and high dose group have conspicuousness effect, and the middle high dose group difference as known to figure
Less.
4.2 inflammatory factors evaluate antigout effect
Inflammatory factor measurement result
Note：Variance analysis, P** are by reference group of model group<0.01 is extremely notable, p*<0.05 is notable；It is right with the positive
Compare according to group, p##<0.01 is extremely notable.
Data are determined with 10 rat blood serums in upper tableVariance analysis is carried out with one-way anova.
From upper table result, high dose group has compared with model group during the measurement result of hs-CRP is shown
Significant difference, and middle high dose group difference is little；The measurement result of TNFa shows low middle high dose group and model
Group more all has a significant difference, and into dosage correlation reduction, but the difference between middle high dose group be far smaller than it is low in
Difference between dosage；High dose group and model group more all have conspicuousness poor during the measurement result of interleukin-6 is shown
It is different, and middle high dose group difference is little；The measurement result of cyclooxygenase 1 shows that low middle high dose group and model group more all have
Significant difference, and the difference between low middle dosage is far above the difference between middle high dose；The measurement result of prostaglandin E shows
Show that middle high dose group and model group more all have significant difference, and middle high dose group difference is little.Biochemistry refers in summary
Mapping is determined interpretation of result and understood, optimal dose group is that middle dose group is 0.2g/kg.
It the above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
The limitation of the present invention, protection scope of the present invention should be defined by claim limited range.For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, some improvements and modifications can also be made, these change
Enter and retouch and also should be regarded as protection scope of the present invention.
Claims (10)
1. purposes of the black fruit fructus lycii ethanol extract in the food, medicine or health products of prevention or/and treatment gout is prepared.
2. purposes according to claim 1, it is characterised in that：The food, medicine or health products are prevention or/and treatment
Food, medicine or the health products of acute gout.
3. purposes according to claim 1 or 2, it is characterised in that：The food, medicine or health products are the foods of anti-inflammatory
Product, medicine or health products.
4. according to the purposes described in claims 1 to 3 any one, it is characterised in that：The food, medicine or health products are
Reduce the food of the content of at least one of hs-CRP, tumor necrosis factor α, cyclooxygenase 1, prostaglandin E in blood
Product, medicine or health products.
5. according to the purposes described in claims 1 to 3 any one, it is characterised in that：The food, medicine or health products are
Reduce food, medicine or the health products of interleukin-6 content in blood.
6. purposes according to claim 1, it is characterised in that：The food, medicine or health products are reduction or remove urine
Food, medicine or the health products of hydrochlorate crystallization.
7. according to the purposes described in claim 1~6 any one, it is characterised in that：The black fruit fructus lycii ethanol extract is
With black fruit fructus lycii raw material, concentration is extracted to obtain in more than 95%v/v ethanol；Further, the ethanol extract system
During standby, answer lucifuge to operate, also need to handle through suction filtration after extraction.
8. according to the composition described in Claims 1 to 4 any one, it is characterised in that：The black fruit fructus lycii ethanol extract
The content of middle anthocyanidin is more than 50%；Further, anthocyanidin content is in 80%-90%.
9. purposes of the black fruit fructus lycii ethanol extract in interleukin-6 or tumor necrosis factor alpha inhibitors is prepared.
10. purposes of the black fruit fructus lycii ethanol extract in tumor necrosis factor alpha inhibitors are prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710687785.8A CN107375532A (en) | 2017-08-11 | 2017-08-11 | Black fruit fructus lycii extract is preparing the purposes in treating gout product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710687785.8A CN107375532A (en) | 2017-08-11 | 2017-08-11 | Black fruit fructus lycii extract is preparing the purposes in treating gout product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375532A true CN107375532A (en) | 2017-11-24 |
Family
ID=60355634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710687785.8A Pending CN107375532A (en) | 2017-08-11 | 2017-08-11 | Black fruit fructus lycii extract is preparing the purposes in treating gout product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375532A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114957172A (en) * | 2022-04-29 | 2022-08-30 | 中国科学院西北高原生物研究所 | Separation method of lycium ruthenicum anti-inflammatory active ingredients and application of lycium ruthenicum anti-inflammatory active ingredients in anti-inflammatory products |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010174001A (en) * | 2009-02-02 | 2010-08-12 | Tsujido Chemical Corp | Agent for preventing or improving hyperuricemia |
| CN101912480A (en) * | 2010-07-23 | 2010-12-15 | 中国科学院西北高原生物研究所 | Method for preparing procyanidin extract of lycium ruthenicum murr |
| CN102060833A (en) * | 2010-11-29 | 2011-05-18 | 中国科学院西北高原生物研究所 | Method for extracting anthocyanin from lycium ruthenicum fruit |
| KR20110132766A (en) * | 2010-06-03 | 2011-12-09 | 강원대학교산학협력단 | Composition for prevention and treatment of gout, hypertension and cancer comprising acanthopanax senticosus fruits extracts |
| CN104041821A (en) * | 2014-07-02 | 2014-09-17 | 中国科学院西北高原生物研究所 | Lycium ruthenicum murr anthocyanin chewable tablet |
-
2017
- 2017-08-11 CN CN201710687785.8A patent/CN107375532A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010174001A (en) * | 2009-02-02 | 2010-08-12 | Tsujido Chemical Corp | Agent for preventing or improving hyperuricemia |
| KR20110132766A (en) * | 2010-06-03 | 2011-12-09 | 강원대학교산학협력단 | Composition for prevention and treatment of gout, hypertension and cancer comprising acanthopanax senticosus fruits extracts |
| CN101912480A (en) * | 2010-07-23 | 2010-12-15 | 中国科学院西北高原生物研究所 | Method for preparing procyanidin extract of lycium ruthenicum murr |
| CN102060833A (en) * | 2010-11-29 | 2011-05-18 | 中国科学院西北高原生物研究所 | Method for extracting anthocyanin from lycium ruthenicum fruit |
| CN104041821A (en) * | 2014-07-02 | 2014-09-17 | 中国科学院西北高原生物研究所 | Lycium ruthenicum murr anthocyanin chewable tablet |
Non-Patent Citations (4)
| Title |
|---|
| 中国法制出版社: "《中华人民共和国食品安全法 实用版》", 31 May 2015, 中国法制出版社 * |
| 朱振全: "《二十四节气与科学养生 文化养心养生与健康丛书》", 31 October 2013, 金盾出版社 * |
| 李明等: ""中医药治疗痛风的临床研究进展"", 《世界中西医结合杂志》 * |
| 陈莎莎等: ""青藏高原黑果枸杞花青素稳定性评价"", 《天然产物研究与开发》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114957172A (en) * | 2022-04-29 | 2022-08-30 | 中国科学院西北高原生物研究所 | Separation method of lycium ruthenicum anti-inflammatory active ingredients and application of lycium ruthenicum anti-inflammatory active ingredients in anti-inflammatory products |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200506723B (en) | Composition for treating hepatitis C | |
| CN105748543B (en) | A Chinese medicinal composition for treating rheumatic diseases, and its preparation method | |
| CN103933224B (en) | A kind of Chinese medicine composition for treating gout | |
| CN105169017A (en) | Traditional Chinese medicine for treating kidney stone and preparation method of traditional Chinese medicine | |
| CN104689173B (en) | A kind of compound Chinese medicinal preparation for treating gout | |
| CN101406688A (en) | Compound formulation for treating rheumatic arthritis and rheumatoid arthritis | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN107375532A (en) | Black fruit fructus lycii extract is preparing the purposes in treating gout product | |
| CN107334778B (en) | Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product | |
| CN107281323B (en) | Application of lycium ruthenicum powder in preparation of uric acid reducing or gout treating products | |
| CN102228551A (en) | Chinese medicinal composition for preventing and treating injury of gastric mucosa and preparation method thereof | |
| CN104147270B (en) | Treat the Chinese medicine composition of oxyhepatitis | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN109481469A (en) | Application of the drug and colla carapacis et plastri testudinis of a kind of colla carapacis et plastri testudinis treatment gout in preparation treatment gout drug | |
| CN107468816A (en) | A kind of pharmaceutical composition for treating gout | |
| CN101450117A (en) | Rheumatism treatment technique | |
| CN107467568A (en) | A kind of natural composition for preventing or treating gout and application thereof | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN107929669A (en) | A kind of Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN115089674B (en) | Traditional Chinese medicine composition for preventing and treating gout by melting urate calculi, and preparation method and application thereof | |
| CN107496437B (en) | Black fruit fructus lycii is preparing the purposes in anti-trioxypurine product | |
| CN105106773B (en) | A kind of Chinese medicine composition for treating gout | |
| CN105943700A (en) | Traditional Chinese medicine composition capable of tonifying kidney and relieving paralysis and preparation method and application thereof | |
| CN105250368A (en) | Traditional Chinese medicine composition capable of delaying kidney failure as well as preparation method and application of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |
|
| RJ01 | Rejection of invention patent application after publication |